TY - JOUR
T1 - Hodgkin’s disease
T2 - Prognostic factors and short-course regimens
AU - Bartlett, N. L.
AU - Arackal, S. M.
N1 - Publisher Copyright:
© 2000, Current Science Inc.
PY - 2000/4
Y1 - 2000/4
N2 - Both topics discussed in this review, prognostic factors and short-course regimens for Hodgkin’s disease, have been the focus of recent research with the goal of developing tools and treatments that will result in the highest cure rates with the least long-term sequelae. A new “prognostic score” for advanced-stage Hodgkin’s disease and several potential prognostic factors, including soluble CD30, soluble interleukin-2 receptor, activated cytotoxic T-lymphocytes, and Epstein-Barr virus, are discussed. Preliminary reports of short-course chemotherapy regimens with and without radiotherapy for all stages of Hodgkin’s disease are summarized.
AB - Both topics discussed in this review, prognostic factors and short-course regimens for Hodgkin’s disease, have been the focus of recent research with the goal of developing tools and treatments that will result in the highest cure rates with the least long-term sequelae. A new “prognostic score” for advanced-stage Hodgkin’s disease and several potential prognostic factors, including soluble CD30, soluble interleukin-2 receptor, activated cytotoxic T-lymphocytes, and Epstein-Barr virus, are discussed. Preliminary reports of short-course chemotherapy regimens with and without radiotherapy for all stages of Hodgkin’s disease are summarized.
KW - Bulky Mediastinal Disease
KW - Prognostic Score
KW - Simple Prognostic Score
KW - Stanford Versus
KW - Stanford Versus Regimen
UR - http://www.scopus.com/inward/record.url?scp=0034157137&partnerID=8YFLogxK
U2 - 10.1007/s11912-000-0089-6
DO - 10.1007/s11912-000-0089-6
M3 - Article
C2 - 11122839
AN - SCOPUS:0034157137
SN - 1523-3790
VL - 2
SP - 163
EP - 171
JO - Current oncology reports
JF - Current oncology reports
IS - 2
ER -